NCT05758610View on ClinicalTrials.gov

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
NHL, AdultAML, Adult Recurrent
Interventions
DRUG

ETH-155008

"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."

Trial Locations (2)

300020

RECRUITING

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

450003

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Shengke Pharmaceuticals (Jiangsu) Limited, China

INDUSTRY